Efficacy of R‐BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy

• DOI: 10.1111/bjh.16416
• Publication Date: 2020-02-03T15:56:11Z
• Authors: Rory McCulloch; Carlo Visco; Toby A. Eyre; Rebecca Frewin; Neil Phillips; David L. Tucker; Francesca M. Quaglia; Annabel McMillan; Jonathan Lambert; Nicola Crosbie; Simon Rule
• Keywords: Bendamustine; Refractory (planetary science)

Summary Patients with mantle cell lymphoma progressing on Bruton’s tyrosine kinase inhibitor (BTKi) have very poor prognosis and there is currently no standard of care. In this retrospective cohort study, patients BTKi received R‐BAC (rituximab, bendamustine, cytarabine). Overall response rate was 83% (complete 60%) 31% were bridged to allogeneic stem transplant (alloSCT). Median progression‐free survival 10.1 months (95% confidence interval (CI) 6·9–13·3) median overall 12·5 CI 11·0–14·0). those consolidated alloSCT only one patient relapsed. demonstrates a high in the post‐BTKi setting eligible an effective bridge alloSCT.